News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Heat On Roche (RHHBY) To Cut Kadcyla Price After National Institute for Clinical Excellence (NICE) Says "No"



4/23/2014 7:06:14 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Breast cancer care campaigners have slammed draft guidelines from the National Institute for Health and Care Excellence turning down NHS funding for Roche's Kadcyla (trastuzumab emtansine) because it costs "tens of thousands of pounds more than other treatments" The Institute has concluded that despite some evidence of efficacy, extending life in patients with metastatic HER2-positive breast cancer by up to six months, the magnitude of the drug's effect is not enough to justify its high cost and so it does not represent value for money. Kadcyla is currently available to patients in England via the Cancer Drugs Fund, but this is only currently scheduled to run until 2016 and, at around £90,000 per patient, is it unlikely to ever be 'routinely' available on the NHS unless its price drops significantly.

Help employers find you! Check out all the jobs and post your resume.



comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES